Retatrutide (development code LY3437943) is one of the most metabolically potent investigational agents in late-stage development, and its published phase 2 program produced genuinely striking improvements in the exact biomarkers that define insulin resistance fasting insulin, HOMA-IR, hepatic fat, and body weight in adults with obesity, type 2 diabetes, and metabolic dysfunctionassociated steatotic liver disease (MASLD)
Time is fast running out for Australians to legally access compounded replica versions of type 2 diabetes and weight-loss drugs such as semaglutide and tirzepatide, as the federal government moves to close a loophole that has allowed large-scale production to continue unregulated
The gradual onset allows the body to adapt to the medication whilst minimising adverse effects, particularly gastrointestinal symptoms that can occur with rapid dose escalation
Furthermore, Sikiric et al
They, therefore, have favourable effect on glucose metabolism and lead to significant caloric intake reduction and resultant weight reduction, usually in the vicinity of 3 - 8 kg depending on the dose and agent used